Skip to main content
  • Saved

Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma

Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma

Source : https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3205279&p_IsPs=N

Drugs of the Future Drugs Fut 2020, 45(12): 865ISSN 0377-8282Copyright 2020 Clarivate AnalyticsCCC: 0377-8282DOI: 10.1358/dof.2020.45.12.3205279 Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma Routledge, D. Multiple myeloma is a relatively uncommon hematological malignancy with a median age of diagnosis of approximately 65 years of age.